Acticor Biotech: reserved on the downside after an 11% decline

(CercleFinance.com) - Shares in biopharmaceutical company Acticor Biotech were still reserved on the downside on Friday on the Paris Bourse, having lost more than 11% in early morning trading following the discontinuation of a clinical trial.


The biopharmaceutical company explained that the Independent Monitoring Committee (IMC) had recommended stopping the phase 2/3 trial evaluating glenzocimab as an adjunct to mechanical thrombectomy in acute ischemic stroke.

To date, 108 patients have been included in the study, but the futility analysis provided to the IMC only covered the first 78 patients.

The randomized, double-blind, multicenter, placebo-controlled study was designed to measure the efficacy and safety of glenzocimab used as an adjunct to mechanical thrombectomy in the first 24 hours of acute ischemic stroke.

With a decline of over 11% before trading was suspended, Acticor Biotech is currently one of the biggest decliners on the Paris market.

This follows the failure already announced in April of a trial which failed to demonstrate efficacy in the treatment of stroke in patients treated with thrombolysis with or without thrombectomy.

Since the beginning of the year, the company's share price has fallen by 83%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.